Table 1.
Baseline clinical characteristics of the 821 patients with locally advanced nasopharynx of head and neck cancer
| Characteristics | No. of patients (%) |
|---|---|
| Age, years | |
| <45 | 477 (58.1) |
| ≥45 | 344 (41.9) |
| Sex | |
| Male | 617 (75.2) |
| Female | 204 (24.8) |
| Histology, WHO typea | |
| II | 14 (1.7) |
| III | 807 (98.3) |
| Smoking | |
| No | 514 (62.6) |
| Yes | 307 (37.4) |
| Alcohol | |
| No | 695 (84.7) |
| Yes | 126 (15.3) |
| Clinical stageb | |
| III | 350 (42.6) |
| IV | 471 (57.4) |
| T stageb | |
| T1 | 48 (5.8) |
| T2 | 71 (8.6) |
| T3 | 388 (47.3) |
| T4 | 314 (38.2) |
| N stageb | |
| N0 | 36 (4.4) |
| N1 | 311 (37.9) |
| N2 | 261 (31.8) |
| N3 | 213 (25.9) |
| NAC regimens | |
| TPF | 501 (61.0) |
| TP | 194 (23.6) |
| GP | 54 (6.6) |
| PF | 61 (7.4) |
| Othersc | 11 (1.3) |
| NAC cycles | |
| 2 cycles | 393 (47.9) |
| 3 cycles | 392 (47.7) |
| 4 cycles | 36 (4.4) |
Abbreviations: GP Gemcitabine and cisplatin, N Node, NAC Neoadjuvant chemotherapy, PF Cisplatin and 5-fluorouracil, T Tumor, TP Docetaxel and cisplatin, TPF Docetaxel, cisplatin, and 5-fluorouracil, WHO World Health Organization
aWHO Type II refers to the differentiated non-keratinizing carcinoma; WHO Type III refers to the undifferentiated non-keratinizing carcinoma
bAccording to the 8th edition of the AJCC/UICC Staging System
cOthers included patients with alteration of NAC regimens, for example switch from TPF to GP due to adverse events